Literature DB >> 31671926

Reducing chronic obstructive pulmonary disease mortality in Korea: early diagnosis matters.

Yong Il Hwang1,2.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31671926      PMCID: PMC6823558          DOI: 10.3904/kjim.2019.327

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


× No keyword cloud information.
See Article on Page 1272-1278 The prevalence of chronic obstructive pulmonary disease (COPD) in Korea between 2007 and 2015 was about 13% [1], and the total economic costs attributable to COPD were estimated to be approximately 1,245 million USD (1,408 billion KRW) in 2013 [2]. COPD was the third leading cause of death in 2016 worldwide, claiming 3 million lives [3], and ranked 8th in causes of death in Korea in 2018 [4]. However, there have been no Korean studies of mortality rate or causes of death in patients with COPD. In the current issue of the Korean Journal of Internal Medicine, Park et al. [5], using the National Health Insurance Service-National Sample Cohort (NHISNSC) database, report the 5-year mortality rate of newly diagnosed COPD to be 25.4%, and the most common cause of death to be chronic lower respiratory disease. This study makes us reconsider the situation of under-diagnosis and under-treatment of COPD, and provides new data on COPD mortality. The 5-year mortality rate reported in that study differs from that of previous studies. The Lung Health Study (LHS), which enrolled patients with milder COPD, reported a 5-year mortality rate of 2.5% [6]. The 3-year mortality rates reported from the Towards a Revolution in COPD Health (TORCH) study were 13% to 16%, depending on the severity of air-flow limitation [7]. In a Danish population-based cohort study, the 3-year mortality rate was 10.0% in GOLD A and 36.9% in GOLD D [8]. This difference may reflect the fact that Korean COPD patients have more severe disease. It is well known that respiratory failure becomes the predominant cause of death in more advanced COPD patients [9]. This study also showed that only 1.5% of subjects were treated for COPD during the 12-year follow-up period. These results reflect a current situation of under-diagnosis and under- treatment of COPD in Korea. In addition, the proportion of male patients in this study was lower than that of other cohort or epidemiological studies in Korea [10,11]. As the prevalence of COPD is higher than that of the general population among male ever- smokers [12], the issue of under-diagnosis and under-treatment of COPD is more severe for male patients. As there is currently no medical treatment to reduce mortality from COPD [13], early detection and introduction of smoking cessation and COPD education could be an initial step to improve survival in patients with COPD [14]. The Korean Academy of Tuberculosis and Respiratory Diseases has developed Korean COPD guidelines [13], and has distributed various educational materials to improve the diagnosis and treatment of COPD. Additionally, a quality assessment program of COPD management has been conducted since 2014 by the Health Insurance Review and Assessment (HIRA) Service, to improve the quality COPD management [15]. Unfortunately, rates of diagnosis, treatment, and awareness of COPD are still very low [1,15], despite these efforts. Therefore, many COPD patients in Korea are not receiving adequate treatment. COPD is now considered to be caused not only by exposure to smoking or air pollution in adult life but also by poor lung growth as a result of malnutrition, infections, and/or passive exposure to pollutants [16]. For this reason, the role of government is important to address the current situation [16,17]. For example, a national, active care-finding strategy for subjects at high risk for COPD is one potential approach for government to consider, as with the National Lung Cancer Screening Program [18]. It should be kept in mind that COPD is a preventable and treatable disease [13].
  14 in total

1.  It is time for the world to take COPD seriously: a statement from the GOLD board of directors.

Authors:  David M G Halpin; Bartolome R Celli; Gerard J Criner; Peter Frith; M Victorina López Varela; Sundeep Salvi; Claus F Vogelmeier; Ronchang Chen; Kevin Mortimer; Maria Montes de Oca; Zaurbek Aisanov; Daniel Obaseki; Rebecca Decker; Alvar Agusti
Journal:  Eur Respir J       Date:  2019-07-04       Impact factor: 16.671

Review 2.  Mortality in COPD: Role of comorbidities.

Authors:  D D Sin; N R Anthonisen; J B Soriano; A G Agusti
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

3.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

4.  Characteristics of Patients with Chronic Obstructive Pulmonary Disease at the First Visit to a Pulmonary Medical Center in Korea: The KOrea COpd Subgroup Study Team Cohort.

Authors:  Jung Yeon Lee; Gyu Rak Chon; Chin Kook Rhee; Deog Kyeom Kim; Hyoung Kyu Yoon; Jin Hwa Lee; Kwang Ha Yoo; Sang Haak Lee; Sang Yeub Lee; Tae-Eun Kim; Tae-Hyung Kim; Yong Bum Park; Yong Il Hwang; Young Sam Kim; Ki Suck Jung
Journal:  J Korean Med Sci       Date:  2016-03-10       Impact factor: 2.153

Review 5.  Strategies for Management of the Early Chronic Obstructive Lung Disease.

Authors:  Jung Yeon Lee; Chin Kook Rhee; Ki Suck Jung; Kwang Ha Yoo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-07-01

Review 6.  Evaluation of Appropriate Management of Chronic Obstructive Pulmonary Disease in Korea: Based on Health Insurance Review and Assessment Service (HIRA) Claims.

Authors:  Sang Mi Chung; Sung Yong Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-07-03

Review 7.  Recent Trends in the Prevalence of Chronic Obstructive Pulmonary Disease in Korea.

Authors:  Yong Il Hwang; Yong Bum Park; Kwang Ha Yoo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-07-03

Review 8.  Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary.

Authors:  Yong Bum Park; Chin Kook Rhee; Hyoung Kyu Yoon; Yeon Mok Oh; Seong Yong Lim; Jin Hwa Lee; Kwang Ha Yoo; Joong Hyun Ahn
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-06-19

9.  Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study.

Authors:  Seon Cheol Park; Dong Wook Kim; Eun Cheol Park; Cheung Soo Shin; Chin Kook Rhee; Young Ae Kang; Young Sam Kim
Journal:  Korean J Intern Med       Date:  2019-10-16       Impact factor: 2.884

10.  Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea.

Authors:  Changhwan Kim; Younhee Kim; Dong Wook Yang; Chin Kook Rhee; Sung Kyoung Kim; Yong Il Hwang; Yong Bum Park; Young Mok Lee; Seonglim Jin; Jinkyeong Park; Cho Rom Hahm; Chang Han Park; So Yeon Park; Cheol Kweon Jung; Yu Il Kim; Sang Haak Lee; Hyoung Kyu Yoon; Jin Hwa Lee; Seong Yong Lim; Kwang Ha Yoo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.